Screening for familial ovarian cancer: Failure of current protocols to detect ovarian cancer at an early stage according to the International Federation of Gynecology and Obstetrics System

Journal of Clinical Oncology

Volumn 23, Issue 24, 2005, Pages 5589-5596

  Stirling, Diane ^a   Evans, D Gareth R ^a   Pichert, Gabriella ^a   Shenton, Andrew ^a   Kirk, Elaine N ^a   Rimmer, Sylvia ^a   Steel, C Michael ^a   Lawson, Sheila ^a   Busby Earle, R M Camille ^a   Walker, Jane ^a   Lalloo, Fiona I ^a   Eccles, Diana M ^a   Lucassen, Anneke M ^a   Porteous, Mary E ^a  

^a UNIVERSITY HOSPITAL SOUTHAMPTON NHS FOUNDATION TRUST   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CA 125 ANTIGEN;

ARTICLE; CANCER DIAGNOSIS; CANCER RISK; CANCER SCREENING; CANCER STAGING; CONTROLLED STUDY; FAMILIAL CANCER; FEMALE; HUMAN; MAJOR CLINICAL STUDY; OVARY CANCER; PRIORITY JOURNAL; TRANSVAGINAL ECHOGRAPHY; ADULT; BLOOD; CLINICAL TRIAL; ECHOGRAPHY; GENETIC PREDISPOSITION; GENETICS; MASS SCREENING; MULTICENTER STUDY; OVARY TUMOR; RISK ASSESSMENT; STANDARD;

ADULT; CA-125 ANTIGEN; FEMALE; GENETIC PREDISPOSITION TO DISEASE; HUMANS; MASS SCREENING; NEOPLASM STAGING; OVARIAN NEOPLASMS; RISK ASSESSMENT;

EID: 24944542432     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2005.05.097     Document Type: Article

References (35)

1. Bell R, Petticrew M, Luengo S, et al: Screening for ovarian cancer: A systematic review. Health Technol Assess 2:1-84, 1998
2. Chappius PO, Foulkes WD: Overview of the clinical genetics of ovarian cancer, in Morrison PJ, Hodgson SV, Haites NE (eds): Familial Breast and Ovarian Cancer: Genetics, Screening and Management. Cambridge, United Kingdom, Cambridge University Press, 2002, pp 43-72
3. Scottish Intercollegiate Guidelines Network (SIGN): Epithelial Ovarian Cancer. Edinburgh, Scotland, SIGN (75th edition), 2003
4. Office for National Statistics. Cancer Statistics: Registrations. Series MBI No. 24. London, United Kingdom, Her Majesty's Stationery Office, 1997
5. Lynch HT, Bewtra C, Wells IC, et al: Hereditary ovarian cancer, in Lynch HT, Kullander S (eds): Cancer Genetics in Women. Boca Raton, CRC Press, 1987, 49-97
6. Kristensen GB, Trope C: Epithelial ovarian cancer. Lancet 349:113-117, 1997
7. Friedlander ML: Prognostic factors in ovarian cancer. Semin Oncol 25:305-314, 1998
8. Stratton JF, Pharoah P, Smith SK, et al: A systematic review and meta-analysis of family history and risk associated with ovarian cancer. Br J Obstet Gynaecol 105:493-499, 1998
9. Thompson D, Easton DF: Cancer incidence in BRCA1 mutation carriers. J Natl Cancer Inst 94:1358-1365, 2002
10. Ford D, Easton DF, Stratton M, et al: Genetic heterogeneity and penetrance analysis of the BRCA1 and BRCA2 genes in breast cancer families: The Breast Cancer Linkage Consortium. Am J Hum Genet 62:676-689, 1998
11. Aarnio M, Sankila R, Pukkala E, et al: Cancer risk in mutation carriers of DNA-mismatch-repair genes. Int J Cancer 81:214-218, 1999
12. Brinkmann D, Jacobs I: Management of familial ovarian cancer, in Morrison PJ, Hodgson SV, Haites NE (eds): Familial Breast and Ovarian Cancer: Genetics, Screening and Management. Cambridge, United Kingdom, Cambridge University Press, 2002, pp 275-285
13. Macmillan RD: Screening women with a family history of breast cancer: Results from the British familial breast cancer group. Eur J Surg Oncol 26:149-152, 2000
14. Moller P, Borg A, Evans DG, et al: Survival in prospectively ascertained familial breast cancer: Analysis of a series stratified by tumour characteristics, BRCA mutations and oophorectomy. Int J Cancer 101:555-559, 2002
15. Tailor A, Bourne TH, Campbell S, et al: Results from an ultrasound-based familial ovarian cancer screening clinic: A 10-year observational study. Ultrasound Obstet Gynecol 21:378-385, 2003
16. Leide A, Karlan BY, Baldwin RL, et al: Cancer incidence in a population of Jewish women at risk of ovarian cancer. J Clin Oncol 20:1570-1577, 2002
17. Scheuer L, Kauff N, Robinson M, et al: Outcome of preventative surgery and screening for breast and ovarian cancer in BRCA mutation carriers. J Clin Oncol 20:1260-1269, 2002
18. Laframboise S, Nedelcu R, Murphy J, et al: Use of CA125 and ultrasound in high-risk women. Int J Gynecol Cancer 12:86-91, 2002
19. Taylor L, Schwartz PE: Cancer screening in a high risk population: A clinical trial. Ultrasound Med Biol 27:461-466, 2001
20. Karlan BY, Baldwin RL, Lopez-Luevanos E, et al: Peritoneal serous papillary carcinoma, a phenotypic variant of familial ovarian cancer: Implications for ovarian cancer screening. Am J Obstet Gynecol 180:917-928, 1999
21. Dørum A, Heimdal K, Lovslett K, et al: Prospectively detected cancer in familial breast/ ovarian cancer screening. Acta Obstet Gynecol Scand 78:906-911, 1999
22. Dørum A, Kristensen GB, Abeler VM, et al: Early detection of familial ovarian cancer. Eur J Cancer 32:1645-1651, 1996
23. Stratton JF, Thompson D, Bobrow L, et al: The genetic epidemiology of early-onset epithelial ovarian cancer: A population-based study. Am J Hum Genet 65:1725-1732, 1999
24. Werness BA, Ramus SJ, Whittemore AS, et al: Histopathology of familial ovarian tumors in women from families with and without germline BRCA1 mutations. Hum Pathol 31:1420-1424, 2000
25. Hogg R, Freidlander M: Biology of epithelial ovarian cancer: Implications for screening women at high genetic risk. J Clin Oncol 22: 1315-1327, 2004
26. Rufford B, Menon U, Jacobs I: Screening for familial ovarian cancer, in Morrison PJ, Hodgson SV, Haites NE (eds): Familial Breast and Ovarian Cancer: Genetics, Screening and Management. Cambridge, United Kingdom, Cambridge University Press, 2002, pp 220-233
27. Wilson JMG, Junger G. Principle and practice of screening for disease. Public Health Pa pers 34. Geneva, Switzerland, World Health Organisation, 1968
28. Kauff ND, Satagopan JM, Robson ME, et al: Risk-reducing salpingo-oophorectomy in women with a BRCA1 or BRCA2 mutation. N Engl J Med 346:1609-1615, 2002
29. Rebbeck TR, Lynch HT, Neuhausen SL, et al: Prophylactic oophorectomy in carriers of BRCA1 or BRCA2 mutations. N Engl J Med 346:1616-1621, 2002
30. Gynecology Oncology Group (USA). Protocol GOG-0199. Philadelphia, PA, Gynecology Oncology Group, 2003
31. Sheppard R, Fry A, Rush R, et al: Women at risk of ovarian cancer: Attitudes towards and expectations of the familial ovarian cancer clinic. Fam Cancer 1:31-37, 2001
32. Boyd J, Sonoda Y, Federici MG, et al: Clinicopathologic features of BRCA-linked and sporadic ovarian cancer. JAMA 283:2260-2265, 2000
33. McGuire V, Whittemore AS, Norris R, et al: Survival in epithelial ovarian cancer patients with prior breast cancer. Am J Epidemiol 152:528-532, 2000
34. Cass I, Baldwin RL, Varkey T, et al: Improved survival in women with BRCA-associated ovarian cancer. Cancer 97:2187-2195, 2003
35. Ben David Y, Chetrit A, Hirsh-Yechezkel G, et al: Effect of BRCA mutations on the length of survival in epithelial tumors. J Clin Oncol 20:463-466, 2002